The Role of Peptide YY (PYY)Infusions in Inhibiting Food Intake.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00259246
Recruitment Status : Completed
First Posted : November 29, 2005
Last Update Posted : January 21, 2009
EC-FP6 (contract number: LHM-CT-2003-503041)
Aditech Pharma AB
Information provided by:
University of Copenhagen

November 25, 2005
November 29, 2005
January 21, 2009
June 2004
Not Provided
  • Appetite
  • Energy intake
Same as current
Complete list of historical versions of study NCT00259246 on Archive Site
  • Energy expenditure and substrate oxidation
  • Blood parameters
  • Blood pressure and heart rate
Same as current
Not Provided
Not Provided
The Role of Peptide YY (PYY)Infusions in Inhibiting Food Intake.
Fasting and Postprandial Response After Infusion of Saline, PYY1-36 and PYY3-36 and Effects on Appetite, Energy Intake and Energy Expenditure in Overweight/Obese Compared to Normalweight Subjects
The aim of the study is to compare fasting and postprandial PYY levels between overweight/obese and lean subjects during and after an infusion of saline, PYY1-36 or PYY3-36 and to evaluate the efects on appetite, energy intake and energy expenditure.
The study is a randomised dobbelblinded placebo controlled study with 24 male subjects ( 12 lean and 12 overweight/obese subjects). VAS scores are used to assess appetite and two ad libitum meals are served in the hours following the infusion. Energy expenditure is measured by ventilated hood system and blood is sampled during part of the study day.
Not Applicable
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single
Primary Purpose: Treatment
Drug: Peptide YY infusion
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
November 2005
Not Provided

Inclusion Criteria:

  • Normal weight (BMI: 18-23 kg/m2) or 12 overweight/obese (BMI: 27-40 kg/m2)
  • Body weight fluctuations < 5 kg over the past 2 months.
  • Blood pressure normal to mildly hypertensive (<159/99 mm Hg)
  • Non-elite athletes and not planning to change physical activity during the study.

Exclusion Criteria:

  • Any physiological or psychological illnesses that could influence the study results
  • Regular use of medicine
  • Smoking defined as <1 cigarette per day.
  • Substance abuse or dependence.
  • Blood donation within the past 3 months before entering the study
  • Drinking >21 alcoholic units/week.
  • Food allergies.
  • Special diets (e.g. vegetarian) or dislikes to any of the foods served during the study.
Sexes Eligible for Study: Male
20 Years to 50 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
University of Copenhagen
  • EC-FP6 (contract number: LHM-CT-2003-503041)
  • Aditech Pharma AB
Principal Investigator: Arne Astrup, Professor Department of Human Nutrition, RVAU
University of Copenhagen
April 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP